Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Oct;17(1):67-72.
doi: 10.1007/BF01966684.

Immunosuppressive activity and toxicity of cyclosporin A in rats pretreated with high dose cyclophosphamide

Immunosuppressive activity and toxicity of cyclosporin A in rats pretreated with high dose cyclophosphamide

P A Brown et al. Agents Actions. 1985 Oct.

Abstract

Cyclophosphamide (Cy; 150 mg/kg) was administered (i.p.) to groups of Sprague-Dawley rats, followed two days later by immunization with ovalbumin (OVA). From that time, cyclosporin A (CsA; 25 mg/kg) or its vehicle was given (p.o.) for a further 13 days. Control animals tested 14 days after immunization, showed strong Arthus-like and modest delayed-type skin reactions to OVA, in contrast to almost total inhibition in animals tested with Cy, CsA or both. Similar effects were observed with respect to serum anti-OVA antibody levels. Despite itself producing lymphopenia, CsA had no additional effect on the lymphocyte depletion caused by Cy. Both drugs, either alone or in combination, caused neutrophilia and monocytosis. An additional eosinophilia due to Cy was prevented by CsA. Cy induced splenomegaly, nodal extramedullary haemopoiesis and increases in both tissue eosinophils and marrow neutrophils. There was also lymphoid depletion in both spleen and lymph nodes which was enhanced by CsA. Thymic lymphoid atrophy was found only when CsA was given. Despite the powerful immunosuppressive properties of both drugs, detailed biochemical and structural analyses showed no other synergistic toxicity, apart from modest hepatic abnormalities. In particular, there was no enhancement of the nephrotoxicity of CsA.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Agents Actions. 1976 Jul;6(4):468-75 - PubMed
    1. Br J Haematol. 1981 Jun;48(2):227-36 - PubMed
    1. J Immunol. 1981 Nov;127(5):2083-6 - PubMed
    1. Lancet. 1979 Nov 17;2(8151):1033-6 - PubMed
    1. Lancet. 1981 Feb 28;1(8218):470-1 - PubMed

Publication types

MeSH terms